Significantly, our research reveals a possible application of the combined therapy of targeted VCP and anti-PD1 in other cancer varieties, as VCP is universally highly expressed in pan-cancer, and low anti-PD1 response rates are also present in various cancer types like melanoma, renal cancer and colorectal cancer. Here, VCP is linked to renal carcinoma.